Table 3.
Evoked pain test results: effect size analysis from before dosing up until 10 h after dosing
| Pain Test Modalities (Contrast Placebo vs. VX-150) |
||||||
|---|---|---|---|---|---|---|
| Capsaicin | Heat | Cold Pressor | Electrical | Pressure | CPM | |
| PDT |
0.728 °C (P = 0.07) (–0.07 to 1.53) |
0.694 °C (P = 0.01) (0.16 to 1.23) |
14.8% (P = 0.488) (–23.9 to 73.0) |
0.88 mA (P = 0.137) (–0.31 to 2.07) |
–12.3% (P = 0.154) (–27.2 to 5.6) |
–0.147 mA (P = 0.692) (–0.94 to 0.65) |
| PTT |
53.7% (P < 0.001) (24.9 to 89.2) |
0.53 mA (P = 0.428) (–0.84 to 1.89) |
3.2% (P = 0.557) (–7.7 to 15.4) |
0.080 mA (P = 0.748) (–0.439 to 0.60) |
||
| AAC/AUC |
43.5% (P = 0.002) (16.2 to 77.3) |
-61.80 mA*% (P = 0.333) (–192.47 to 68.87) |
–197.28 % (P = 0.445) (–728.62 to 334.05) |
24.38 mA*% (P = 0.4098) (–36.86 to 85.62) |
||
Numbers represent estimates of the difference with P values and 95% CIs in parentheses. Values are presented in % for tests for which the data were log-transformed (i.e., cold pressor and pressure pain tests). Otherwise, data are given in the unit in which they were measured. Values in boldfaced italic denote nominal significance (P < 0.05). Estimates >0 favor VX-150. Estimates <0 favor placebo. °C = degrees Celsius; CPM = conditioned pain modulation paradigm; AAC/AUC = area above/under the eVAS pain curve; eVAS = electronic Visual Analogue Scale; mA = milliampere; PDT = pain detection threshold; PTT = pain tolerance threshold.